

# Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/G504C49C446BEN.html>

Date: September 2022

Pages: 65

Price: US\$ 3,500.00 (Single User License)

ID: G504C49C446BEN

## Abstracts

Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Glycoprotein 41 - Drugs In Development, 2022, outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 5 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).

Furthermore, this report also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued

projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)

The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects

The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Glycoprotein 41 (gp41) - Overview

Glycoprotein 41 (gp41) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glycoprotein 41 (gp41) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glycoprotein 41 (gp41) - Companies Involved in Therapeutics Development

Frontier Biotechnologies Inc

Longevity Biotech Inc

MacroGenics Inc

Minka Therapeutics SA

Molecular Express Inc

Mymetics Corp

Navigen Inc

Novodux

Osel Inc

Protheragen Inc

Glycoprotein 41 (gp41) - Drug Profiles

albuvirtide LA - Drug Profile

Product Description

Mechanism Of Action

History of Events

CI3hmAb - Drug Profile

Product Description

Mechanism Of Action

History of Events

CPT-31 - Drug Profile

Product Description

Mechanism Of Action

History of Events

DS-007 - Drug Profile

Product Description

Mechanism Of Action

History of Events

HIV-1 vaccine - Drug Profile

Product Description

Mechanism Of Action

human immunodeficiency virus (virus like particles) vaccine - Drug Profile

Product Description

Mechanism Of Action

LBT-5001 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MGD-020 - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies to Target GP120 and GP41 for HIV - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Target GP41 for HIV Infections - Drug Profile

Product Description

Mechanism Of Action

History of Events

MPER-656 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MYMV-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Peptides to Inhibit gp41 for HIV-1 Infection - Drug Profile

Product Description

Mechanism Of Action

Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Target GP120 and Gp41 for HIV-1 Infections - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Inhibit GP41 for HIV Infections - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile

Product Description

Mechanism Of Action

VAC-02 - Drug Profile

Product Description

Mechanism Of Action

VAC-3S - Drug Profile

Product Description

Mechanism Of Action

History of Events

Glycoprotein 41 (gp41) - Dormant Products

Glycoprotein 41 (gp41) - Discontinued Products

Glycoprotein 41 (gp41) - Product Development Milestones

Featured News & Press Releases

Dec 27, 2021: Frontier Bio's "Spring Breeze Program" is dedicated to the treatment of AIDS patients in low-income areas

Nov 26, 2021: "China AIDS Diagnosis and Treatment Guidelines (2021 Edition)" introduces Aikening as a recommended treatment plan for post-exposure prevention of AIDS

Oct 27, 2021: Frontier Biotechnologies long-acting injectable (Aikening(R)), in a two drug regimen, proves safe and effective for critically ill hospitalized AIDS patients

Jul 19, 2021: Frontier biotechnologies first long-acting injectable (Aikening), in a two drug regimen for HIV, proves safe and efficacious for patients

Dec 10, 2019: Navigen announces FDA clearance of its IND application to initiate first-in-human studies for CPT31, a novel, D-peptide HIV entry inhibitor

Apr 29, 2019: Mymetics receives funding from NIH for Novel HIV Vaccine Study

Aug 21, 2018: Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA

Jun 07, 2018: Frontier Biotech receives marketing authorization from China FDA for Aikening (albuvirtide for injection), China's first new drug for the treatment of HIV

Sep 18, 2017: Navigen Awarded \$4.9MM to Advance its HIV Entry Inhibitor CPT31

Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines

Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science

Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen's HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting

Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development

Aug 24, 2016: Navigen Awarded \$500,000 Grant to Support Depot Formulation of its HIV Drug Candidate

Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Frontier Biotechnologies Inc, 2022

Pipeline by Longevity Biotech Inc, 2022

Pipeline by MacroGenics Inc, 2022

Pipeline by Minka Therapeutics SA, 2022

Pipeline by Molecular Express Inc, 2022

Pipeline by Mymetics Corp, 2022

Pipeline by Navigen Inc, 2022

Pipeline by Novodux, 2022

Pipeline by Osel Inc, 2022

Pipeline by Protheragen Inc, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Glycoprotein 41 (gp41) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/G504C49C446BEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G504C49C446BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

